The falsification happened in the case of the both approved and pending drug application, the regulator said. Health Canada didn't give details of the type and quantum of drugs Ranbaxy's Canadian unit imports into the country. The watchdog also did not issue a separate advisory for users of drugs. Ranbaxy's New Delhi-based spokesperson declined to comment on the development. This is the second instance where US drug regulator's warning to Ranbaxy has evoked a response from its Canadian counterpart. In September 2008, when US announced a ban on Ranbaxy's 30 products manufacturing from its Paonta Sahib and Dewas facilities, Health Canada had sent a letter to Ranbaxy's Canadian subsidiary requesting an action plan and response to the FDA warning letter.